COMPASS Pathways plc (CMPS)
NASDAQ: CMPS · Real-Time Price · USD
3.845
+0.085 (2.26%)
May 9, 2025, 11:09 AM - Market open
COMPASS Pathways Employees
COMPASS Pathways had 166 employees as of December 31, 2024. The number of employees decreased by 20 or -10.75% compared to the previous year.
Employees
166
Change (1Y)
-20
Growth (1Y)
-10.75%
Revenue / Employee
n/a
Profits / Employee
-$830,114
Market Cap
356.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 166 | -20 | -10.75% |
Dec 31, 2023 | 186 | 5 | 2.76% |
Dec 31, 2022 | 181 | 65 | 56.03% |
Dec 31, 2021 | 116 | 54 | 87.10% |
Dec 31, 2020 | 62 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CMPS News
- 1 day ago - COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights - Business Wire
- 10 days ago - Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities - Business Wire
- 11 days ago - Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 - Business Wire
- 17 days ago - Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire
- 5 weeks ago - This Is a Test From GlobeNewswire - GlobeNewsWire
- 6 weeks ago - Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire
- 7 weeks ago - Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression - Business Wire